Abnormal hCG levels in a patient with treated stage I seminoma: a diagnostic dilemma

Department of Radiation Oncology, St, Luke's Hospital, Dublin, Ireland.
World Journal of Surgical Oncology (Impact Factor: 1.2). 02/2008; 6:68. DOI: 10.1186/1477-7819-6-68
Source: PubMed

ABSTRACT We report the case of a patient with treated Stage Ia seminoma who was found to have an elevated beta human chorionic gonadotrophin (hCG) on routine follow - up. This instigated restaging and could have lead to commencement of chemotherapy.
The patient was a bodybuilder, and following a negative metastatic work - up, admitted to injecting exogenous beta hCG. This was done to reduce withdrawal symptoms from androgen abuse. The patient remains well eight years post diagnosis.
This case highlights the need for surgical oncologists to conduct vigilant screening of young male patients with a history of testicular germ cell tumours and who may indulge in steroid abuse.

Download full-text


Available from: Noel Aherne, Aug 03, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: We detail the case history of a patient with Stage I seminoma, who developed an elevated level of human chorionic gonadotrophin (hCG) while on follow-up. It transpired that the patient had injected himself with hCG several days before. This type of abuse has been documented, but this is the first reported case of it interfering with the follow-up of a patient with a germ cell tumour.
    Clinical Oncology 02/1998; 10(2):131-2. DOI:10.1016/S0936-6555(05)80495-9 · 2.83 Impact Factor
  • The Lancet 01/1952; 2(6696):1195-7. DOI:10.1016/S0140-6736(51)93202-3 · 45.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess the possibility of reducing radiotherapy doses without compromising efficacy in the management of patients with stage I seminoma. Patients were randomly assigned 20 Gy/10 fractions over 2 weeks or 30 Gy/15 fractions during 3 weeks after orchidectomy. They completed a symptom diary card during treatment and quality-of-life forms pre- and post-treatment. The trial was powered to exclude absolute differences in 2-year relapse rates of 3% to 4% (alpha = .05 [one sided]; 90% power). From 1995 to 1998, 625 patients were randomly assigned to treatment. Four weeks after starting radiotherapy, significantly more patients receiving 30 Gy reported moderate or severe lethargy (20% v 5%) and an inability to carry out their normal work (46% v 28%). However, by 12 weeks, levels in both groups were similar. With a median follow-up of 61 months, 10 and 11 relapses, respectively, have been reported in the 30- and 20-Gy groups (hazard ratio, 1.11; 90% CI, 0.54 to 2.28). The absolute difference in 2-year relapse rates is 0.7%; the lower 90% confidence limit is 2.9%. Only one patient has died from seminoma (allocated to the 20-Gy treatment group). Treatment with 20 Gy in 10 fractions is unlikely to produce relapse rates more than 3% higher than for standard 30 Gy radiation therapy, and data on an additional 469 patients randomly assigned in a subsequent trial support and strengthen these results. Reductions in morbidity enable patients to return to work more rapidly. Prolonged follow-up is required before any inference can be made about any impact of allocated treatment on new primary cancer diagnoses.
    Journal of Clinical Oncology 03/2005; 23(6):1200-8. DOI:10.1200/JCO.2005.08.003 · 18.43 Impact Factor